Title:Evolving Strategies in NSCLC Care: Targeted Therapies,
Biomarkers, Predictive Models, and Patient Management
Volume: 20
Issue: 3
Author(s): Janmejay Pant*, Payal Mittal*, Lovedeep Singh and Harneet Marwah
Affiliation:
- University Institute of Pharma Sciences, Chandigarh University, Punjab, India
- University Institute of Pharma Sciences, Chandigarh University, Punjab, India
Keywords:
Genetic mutation, lung cancer, NSCLC, EGFR, potential therapies, biomarkers.
Abstract:
Lung cancer, primarily Non-Small Cell Lung Cancer (NSCLC), is a global
public health concern responsible for 80-85% of cases, with over two million new cases
occurring annually, and 50% of them in Asia. While there has been a gradual reduction in
United States (US) cases over the last decade, with 238,340 new cases and 127,070
deaths reported in 2023, managing metastatic NSCLC remains crucial, focusing on prolonging
survival and enhancing quality of life. Integration of early palliative care shows
promise in this regard. International guidelines recommend personalized treatment guided
by genetic mutations (Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma
Kinase, C-Ros oncogene [1ROS1]) and systemic therapies, including chemotherapy,
targeted therapy, and immunotherapy, which play pivotal roles in redefining care. Treatment
effectiveness hinges on factors such as cancer stage, patient health, and therapy
type, with surgery and radiation therapy common in early stages and advanced stages requiring
chemotherapy, targeted therapy, or immunotherapy. Despite advancements in
treatment modalities, NSCLC continues to pose a significant challenge globally, particularly
in Asia, where a substantial portion of new cases arise. While there has been an uncertain
reduction in the incidence of lung cancer in the US over the past decade, the burden
of the disease persists, with substantial mortality rates reported annually.
Additionally, upon diagnosis, many NSCLC patients present with distant metastases, necessitating
effective treatment strategies to improve overall survival and quality of life.
The objectives include investigating targeted treatments for NSCLC with specific genetic
mutations, examining mechanisms of novel therapies under study, evaluating preclinical
and clinical studies for therapy efficacy and safety, identifying genetic and epigenetic biomarkers
for diagnosis, prognosis, and treatment selection, developing predictive models
for lung cancer recurrence and survival, assessing the efficacy of treatment approaches
for early-stage lung cancer, and enhancing patient outcomes through collaborative care
and lifestyle interventions. These collective efforts promise to improve patient outcomes
and quality of life in the battle against NSCLC.
